CN105384687B - 喹啉酮类化合物及其在药物中应用 - Google Patents
喹啉酮类化合物及其在药物中应用 Download PDFInfo
- Publication number
- CN105384687B CN105384687B CN201510557206.9A CN201510557206A CN105384687B CN 105384687 B CN105384687 B CN 105384687B CN 201510557206 A CN201510557206 A CN 201510557206A CN 105384687 B CN105384687 B CN 105384687B
- Authority
- CN
- China
- Prior art keywords
- methyl
- independently
- oxo
- alkyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c(c(*)c1C(O)=C2C(NCC(O)=O)=O)c(*)c(*)c1N(*)C2=O Chemical compound *c(c(*)c1C(O)=C2C(NCC(O)=O)=O)c(*)c(*)c1N(*)C2=O 0.000 description 4
- YWVWMONXVDELOX-UHFFFAOYSA-N CC(C(N(C)C1=[I]C=CC(OC(C=CC2)=CC2=[F])=CC=C11)=[O]=C)=C1O Chemical compound CC(C(N(C)C1=[I]C=CC(OC(C=CC2)=CC2=[F])=CC=C11)=[O]=C)=C1O YWVWMONXVDELOX-UHFFFAOYSA-N 0.000 description 1
- WKACUVXGXQFRMZ-KPEOIQKJSA-N CN(c(cc(cc1)OC/C=C(\C=C(/C=C)\Cl)/F)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)OC/C=C(\C=C(/C=C)\Cl)/F)c1C(O)=C1C(NCC(O)=O)=O)C1=O WKACUVXGXQFRMZ-KPEOIQKJSA-N 0.000 description 1
- QRBJEOYTJIOYRT-UHFFFAOYSA-N CN(c(cc(cc1)Oc(cc2)ccc2OC)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc(cc2)ccc2OC)c1C(O)=C1C(NCC(O)=O)=O)C1=O QRBJEOYTJIOYRT-UHFFFAOYSA-N 0.000 description 1
- KZVACICDHIJYPM-UHFFFAOYSA-N CN(c(cc(cc1)Oc(cccc2)c2OC(F)(F)F)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc(cccc2)c2OC(F)(F)F)c1C(O)=C1C(NCC(O)=O)=O)C1=O KZVACICDHIJYPM-UHFFFAOYSA-N 0.000 description 1
- DXSIQMMMGZQOEX-UHFFFAOYSA-N CN(c(cc(cc1)Oc2cc(Cl)ccc2F)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc2cc(Cl)ccc2F)c1C(O)=C1C(NCC(O)=O)=O)C1=O DXSIQMMMGZQOEX-UHFFFAOYSA-N 0.000 description 1
- ICXAYMXZQDDPME-UHFFFAOYSA-N CN(c(cc(cc1)Oc2cc(F)ccc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc2cc(F)ccc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O ICXAYMXZQDDPME-UHFFFAOYSA-N 0.000 description 1
- UOXGSAQMWYGJJW-UHFFFAOYSA-N CN(c(cc(cc1)Oc2cc(cccc3)c3cc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc2cc(cccc3)c3cc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O UOXGSAQMWYGJJW-UHFFFAOYSA-N 0.000 description 1
- YWAUYPYFFKKBFV-UHFFFAOYSA-N CN(c(cc(cc1)Oc2ccncc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(cc(cc1)Oc2ccncc2)c1C(O)=C1C(NCC(O)=O)=O)C1=O YWAUYPYFFKKBFV-UHFFFAOYSA-N 0.000 description 1
- UZGBENGFNVWPQF-UHFFFAOYSA-N CN(c(ccc(Oc1ccccc1)c1)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c(ccc(Oc1ccccc1)c1)c1C(O)=C1C(NCC(O)=O)=O)C1=O UZGBENGFNVWPQF-UHFFFAOYSA-N 0.000 description 1
- LHOARXWSUMAVHS-UHFFFAOYSA-N CN(c1cc(Oc(cccc2)c2Cl)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c1cc(Oc(cccc2)c2Cl)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O LHOARXWSUMAVHS-UHFFFAOYSA-N 0.000 description 1
- JRJDZFSTCZSDLQ-UHFFFAOYSA-N CN(c1cc(Oc(cccc2)c2F)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CN(c1cc(Oc(cccc2)c2F)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O JRJDZFSTCZSDLQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510557206.9A CN105384687B (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其在药物中应用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410442574 | 2014-09-02 | ||
| CN2014104425744 | 2014-09-02 | ||
| CN201510557206.9A CN105384687B (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其在药物中应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105384687A CN105384687A (zh) | 2016-03-09 |
| CN105384687B true CN105384687B (zh) | 2018-05-01 |
Family
ID=55417512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510557206.9A Active CN105384687B (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其在药物中应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10065928B2 (enExample) |
| EP (1) | EP3190104B1 (enExample) |
| JP (1) | JP6506390B2 (enExample) |
| CN (1) | CN105384687B (enExample) |
| AU (1) | AU2015311333B2 (enExample) |
| CA (1) | CA2959688C (enExample) |
| ES (1) | ES2898476T3 (enExample) |
| WO (1) | WO2016034108A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111269176A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN111269178A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
| CN108069952B (zh) * | 2016-11-08 | 2022-09-27 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其在药物中应用 |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CN108285460A (zh) * | 2017-01-09 | 2018-07-17 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的药用盐及其制备方法与用途 |
| JP6999469B2 (ja) * | 2018-03-28 | 2022-01-18 | 東京応化工業株式会社 | 水素バリア剤、水素バリア膜形成用組成物、水素バリア膜、水素バリア膜の製造方法、及び電子素子 |
| CN111269177B (zh) * | 2019-11-28 | 2023-05-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型 |
| CN112851581B (zh) * | 2019-11-28 | 2022-08-12 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010663A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010662B (zh) * | 2021-03-05 | 2023-12-08 | 广东东阳光药业股份有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010664A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN114989085B (zh) * | 2022-05-23 | 2023-11-24 | 安徽医科大学 | 一种芳基内酰胺环类化合物、药物组合物及其应用 |
| CN117159549B (zh) * | 2023-10-11 | 2025-02-14 | 中国药科大学 | 一种酯类化合物的应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1644336T3 (pl) * | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
| WO2006088246A1 (ja) * | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Ｇｐｒ３４受容体機能調節剤 |
| CN101166745A (zh) | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | 噻吩并吡啶化合物和其使用方法 |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| JP5202327B2 (ja) * | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| KR101446499B1 (ko) | 2006-01-27 | 2014-10-06 | 피브로겐, 인크. | 저산소증 유발가능 인자(ｈｉｆ)를 안정시키는 시아노이소퀴놀린 화합물 |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| CA2647596C (en) | 2006-04-04 | 2012-06-12 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
| WO2007136990A2 (en) | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| AR061570A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| PL3357911T3 (pl) | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| WO2008076425A1 (en) | 2006-12-18 | 2008-06-26 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| AU2007334323B2 (en) | 2006-12-18 | 2011-03-10 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| US7569726B2 (en) | 2007-04-18 | 2009-08-04 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| EP2136810A4 (en) * | 2007-04-18 | 2012-01-04 | Merck Sharp & Dohme | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS |
| ES2442847T3 (es) | 2007-04-18 | 2014-02-13 | Amgen, Inc | Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa |
| AU2008248234B2 (en) | 2007-05-04 | 2011-02-03 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| CN101815718A (zh) | 2007-08-10 | 2010-08-25 | 克里斯捷诺米有限公司 | 吡啶衍生物及其用法 |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039322A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| AU2008329746A1 (en) | 2007-11-30 | 2009-06-04 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| JP2011508725A (ja) | 2007-11-30 | 2011-03-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| EP2240178A4 (en) | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| CN101951777A (zh) | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢呋喃并吡啶酮 |
| JP2011513222A (ja) | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロチエノピリジン |
| JP2011513223A (ja) | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロ−１ｈ−ピロロ縮合ピリドン |
| WO2009134750A1 (en) | 2008-04-28 | 2009-11-05 | Janssen Pharmaceutica Nv | Benzoimidazoles as prolyl hydroxylase inhibitors |
| US20110039895A1 (en) | 2008-04-30 | 2011-02-17 | Glaxo Smith Kline LLC., a corporation | Prolyl hydroxylase inhibitors |
| WO2009134847A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009158315A1 (en) | 2008-06-25 | 2009-12-30 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| EP2326178A4 (en) | 2008-08-21 | 2012-10-24 | Glaxosmithkline Llc | INHIBITORS OF PROLYL-HYDROXYLASE |
| JP2012500850A (ja) | 2008-08-25 | 2012-01-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| EP2370422B1 (en) | 2008-11-14 | 2019-06-05 | Fibrogen, Inc. | Thiochromene derivatives as hif hydroxylase inhibitors |
| ES2548250T3 (es) | 2009-02-10 | 2015-10-15 | Janssen Pharmaceutica, N.V. | Quinazolinonas como inhibidores de prolilhidroxilasa |
| KR20120065311A (ko) | 2009-07-15 | 2012-06-20 | 씬산 강 | 저산소증 모방체인 화합물, 및 그의 조성물 및 용도 |
| DK2455381T5 (en) | 2009-07-17 | 2015-02-09 | Japan Tobacco Inc | Triazolopyridinforbindelse and its effect as an inhibitor of prolyl hydroxylase and induce erythropoietin production by |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| TWI500623B (zh) | 2009-10-13 | 2015-09-21 | Torrent Pharmaceuticals Ltd | 新穎稠合噻唑及噁唑嘧啶酮 |
| WO2011056725A1 (en) | 2009-11-05 | 2011-05-12 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| US8541430B2 (en) | 2009-11-27 | 2013-09-24 | Torrent Pharmaceuticals Limited | Fused thiazolo and oxazolo pyrimidinones |
| JP5755741B2 (ja) | 2010-08-13 | 2015-07-29 | ヤンセン ファーマシューティカ エヌ．ベー． | プロリルヒドロキシラーゼインヒビタとしての４−アミノキナゾリン−２−イル−１−ピラゾール−４−カルボン酸化合物 |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| CA2837560C (en) | 2011-06-06 | 2017-02-14 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| EP2736892A4 (en) | 2011-07-29 | 2015-03-18 | Beijing Betta Pharmaceuticals Co Ltd | STABLE POLYMORPHIC FORMS OF A CONNECTION AS HYPOXIEMIMETICS AND USES THEREOF |
| NZ700760A (en) | 2012-03-09 | 2016-08-26 | Fibrogen Inc | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| CA2879238C (en) | 2012-07-16 | 2021-08-10 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| SG11201500720WA (en) | 2012-07-30 | 2015-04-29 | Taisho Pharmaceutical Co Ltd | Partially saturated nitrogen-containing heterocyclic compound |
| TW201412744A (zh) | 2012-08-23 | 2014-04-01 | Mitsubishi Tanabe Pharma Corp | 吡唑并嘧啶化合物 |
| AU2013368843B2 (en) * | 2012-12-24 | 2016-02-25 | Zydus Lifesciences Limited | Novel quinolone derivatives |
| JP6437456B2 (ja) | 2013-01-24 | 2018-12-12 | フィブロジェン インコーポレイテッド | ｛［１−シアノ−５−（４−クロロフェノキシ）−４−ヒドロキシ−イソキノリン−３−カルボニル］−アミノ｝−酢酸の結晶形態 |
-
2015
- 2015-09-01 WO PCT/CN2015/088799 patent/WO2016034108A1/zh not_active Ceased
- 2015-09-01 JP JP2017512046A patent/JP6506390B2/ja active Active
- 2015-09-01 US US15/502,499 patent/US10065928B2/en active Active
- 2015-09-01 CN CN201510557206.9A patent/CN105384687B/zh active Active
- 2015-09-01 EP EP15837609.5A patent/EP3190104B1/en active Active
- 2015-09-01 AU AU2015311333A patent/AU2015311333B2/en active Active
- 2015-09-01 ES ES15837609T patent/ES2898476T3/es active Active
- 2015-09-01 CA CA2959688A patent/CA2959688C/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111269176A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN111269178A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6506390B2 (ja) | 2019-04-24 |
| EP3190104A4 (en) | 2018-04-11 |
| CA2959688A1 (en) | 2016-03-10 |
| AU2015311333B2 (en) | 2017-11-16 |
| US20170247332A1 (en) | 2017-08-31 |
| CN105384687A (zh) | 2016-03-09 |
| WO2016034108A1 (zh) | 2016-03-10 |
| CA2959688C (en) | 2024-02-27 |
| JP2017525737A (ja) | 2017-09-07 |
| ES2898476T3 (es) | 2022-03-07 |
| AU2015311333A1 (en) | 2017-02-16 |
| EP3190104B1 (en) | 2021-10-27 |
| EP3190104A1 (en) | 2017-07-12 |
| US10065928B2 (en) | 2018-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105384687B (zh) | 喹啉酮类化合物及其在药物中应用 | |
| CN109400625B (zh) | 稠合双环类化合物及其在药物中的应用 | |
| CN110770233B (zh) | 稠合双环类化合物及其在药物中的应用 | |
| WO2015158310A1 (zh) | 一种酪氨酸激酶抑制剂及其用途 | |
| WO2023051716A1 (zh) | 杂芳基衍生物parp抑制剂及其用途 | |
| CN103664899B (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| CN110511219A (zh) | 苯基取代的二氢萘啶类化合物及其用途 | |
| CN109988093B (zh) | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 | |
| CN109988106B (zh) | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 | |
| CN118525022A (zh) | 一种氮杂并环衍生物及其在医药上的应用 | |
| CN108069952B (zh) | 喹啉酮类化合物及其在药物中应用 | |
| CN107793409B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN111217811B (zh) | 稠合三环类化合物及其在药物中的应用 | |
| WO2020259703A1 (zh) | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 | |
| CN108069957B (zh) | 脯氨酰羟化酶抑制剂及其用途 | |
| WO2022156758A1 (zh) | 新型酰胺吡咯类化合物及其在药物中的用途 | |
| CN110903284B (zh) | 稠合三环类化合物及其在药物中的应用 | |
| WO2011124093A1 (zh) | 双环喹诺酮类化合物及其制备和应用 | |
| WO2024099225A1 (zh) | Ulk抑制剂 | |
| WO2023274396A1 (zh) | 苯并氮杂环类化合物及其在药物中的应用 | |
| CN117321036A (zh) | 具有抗癌活性的苯基-o-喹啉、喹唑啉、噻吩并吡啶、噻吩并嘧啶、吡咯并吡啶、吡咯并嘧啶化合物 | |
| WO2023179078A1 (zh) | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 | |
| WO2022143610A1 (zh) | 新型酰胺吡咯类化合物及其在药物中的应用 | |
| WO2023020512A1 (zh) | 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途 | |
| CN117003754A (zh) | 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160309 Assignee: Nianyan Pharmaceutical (Shanghai) Co.,Ltd. Assignor: SUNSHINE LAKE PHARMA Co.,Ltd. Contract record no.: X2021980013023 Denomination of invention: Quinolone compounds and their application in medicine Granted publication date: 20180501 License type: Exclusive License Record date: 20211124 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| CP03 | Change of name, title or address |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan) Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Nianyan Pharmaceutical (Shanghai) Co.,Ltd. Assignor: SUNSHINE LAKE PHARMA Co.,Ltd. Contract record no.: X2021980013023 Date of cancellation: 20241010 |
|
| EC01 | Cancellation of recordation of patent licensing contract |